COST-EFFECTIVENESS OF BEVACIZUMAB VERSUS CETUXIMAB VERSUS PANITUMUMAB COMBINED WITH FIRST-LINE FOLFOX FOR METASTATIC COLORECTAL CANCER IN BRAZIL

被引：0
|
作者：
Sasse, Andre [1 ]
Carvalho, Adriana [1 ]
机构：
[1] Univ Estadual Campinas, UNICAMP, Ctr Evidence Oncol, CEVON, Campinas, SP, Brazil
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：100 / 100
页数：1
相关论文
共 50 条
  • [31] Pharmacoeconomic analysis of XELOX versus FOLFOX for metastatic colorectal cancer first-line treatment in Taiwan
    Chen, H. -H.
    Chang, C. -S.
    Chen, L. -T.
    Chen, W. T. -L.
    Hsu, T. -C.
    Wang, J. -Y.
    ANNALS OF ONCOLOGY, 2015, 26 : 54 - 54
  • [32] COST-MINIMIZATION ANALYSIS OF BEVACIZUMAB COMPARED TO CETUXIMAB AND PANITUMUMAB IN FIRST-LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER IN FRANCE
    Gherardi, A.
    Masia, C.
    Plommet, N.
    VALUE IN HEALTH, 2016, 19 (07) : A738 - A738
  • [33] Bevacizumab in addition to chemotherapy first-line for right-side metastatic colorectal cancer: A cost-effectiveness analysis.
    Chen, Gong
    Liu, Maobai
    Li, Te
    Wu, Bin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [34] First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Chiang, Chi-Leung
    Chan, Sik-Kwan
    Lee, Shing-Fung
    Choi, Horace Cheuk-Wai
    CANCERS, 2021, 13 (05) : 1 - 13
  • [35] First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Choi, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S97 - S97
  • [36] Comparative Effectiveness of Cetuximab Versus Panitumumab in Patients With Metastatic Colorectal Cancer: A Nationwide Database Study
    Wu, Chih-chien
    Su, Chien-chou
    Chen, Yu-hsun
    Hsu, Chao-wen
    Hsieh, Meng-che
    Chang, Yu-ching
    Wang, Yung-chang
    Su, Yi-chia
    ANTICANCER RESEARCH, 2023, 43 (11) : 5127 - 5138
  • [37] Effect of bevacizumab combined with first-line chemotherapy on metastatic colorectal cancer
    Xiong, Lifeng
    Lou, Yinmei
    Wang, Lin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (04): : 3609 - 3617
  • [38] Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
    Braghiroli, Maria Ignez Freitas Melro
    Filho, Daniel Santos Rocha Sobral
    Fagundes, Juliana Goes Martins
    Mendoza, Elizabeth Zambrano
    Neffa, Maria Fernanda Batistuzzo Vicentini
    Campos, Karla Souza
    da Fonseca, Leonardo Gomes
    Bonadio, Renata Colombo
    Talans, Aley
    Braghiroli, Oddone Freitas Melro
    Mathias-Machado, Maria Cecilia
    Sabbaga, Jorge
    Venchiarutti, Camila Motta
    Hoff, Paulo Marcelo Gehm
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 42
  • [39] COST-MINIMIZATION ANALYSIS OF BEVACIZUMAB VERSUS CETUXIMAB IN FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN KRAS WILD-TYPE PATIENTS IN THE SUPPLEMENTARY HEALTH CARE SYSTEM IN BRAZIL
    Tsuchiya, C. T.
    Kim, H. S. J.
    Maximo, M. F. M.
    Ramos, L. A.
    VALUE IN HEALTH, 2014, 17 (07) : A641 - A641
  • [40] Clinical and Cost Effectiveness of Bevacizumab plus FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea
    Lee, Eui-Kyung
    Revil, Cedric
    Ngoh, Charles A.
    Lister, Johanna
    Kwon, Jeong-Mi
    Park, Mee-Hye
    Park, Seok-Jin
    Park, Young-Suk
    Shin, Sang-Joon
    Lee, Myung-Ah
    Lee, Nam-Su
    Zang, Dae-Young
    Bae, Eun-Jin
    Kang, Mi-Jeong
    CLINICAL THERAPEUTICS, 2012, 34 (06) : 1408 - 1419
12345